Singapore Clinical Trial: Responses Against Paramyxoviruses in T cells with crOss Reactivity

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Responses Against Paramyxoviruses in T cells with crOss Reactivity'. The following are the other rel... Read More

Singapore Clinical Trial: Effect of innate immune reprogramming by primary dengue on host response to secondary dengue

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The f... Read More

Singapore Clinical Trial: Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Voiding: A case controlled study

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Voidi... Read More

Singapore Clinical Trial: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembro... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More

Singapore Clinical Trial: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nera... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4302814 in Healthy Participants

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Do... Read More

Singapore Clinical Trial: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More

• ««
• «
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• »
• »»